Neurodegeneration Research: From Molecules, Big Animal Models To Human Beings | 57422
Journal of Alzheimers Disease & Parkinsonism
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Appropriate connections or interactions among different neural cell types are essential for the correct and efficient functioning
of the nervous system during development and regeneration after trauma or degeneration. The aim of my research is to
understand the molecular events that mediate communication among neural cells in the nervous system during development,
myelination, learning and memory, degeneration, and regeneration. These studies have yielded insights into the therapeutic
potential of cell signalling molecules to ameliorate or even ablate the detrimental consequences of nervous system injury and
neurodegenerative diseases, including stroke, traumatic brain injury, spinal cord injury, Alzheimer Disease (AD), and Multiple
Sclerosis (MS). Using genome-wide chromatin immunoprecipitation approaches, we found that AICD is specifically recruited
to the regulatory regions of several microRNA genes, and acts as a transcriptional regulator for miR-663, by which suppresses
neuronal differentiation in human neural stem cells. We have generated transgenic pigs expressing mutant G93A hSOD1
and showing hind limb motor defects, which are germline transmissible, and motor neuron degeneration in dose- and agedependent
manners. Furthermore, in a case report we present the treatment of aggressive MS patient with multiple allogenic
human umbilical cord-derived mesenchymal stem cell and autologous bone marrow-derived mesenchymal stem cells over a 4
y period. The treatments were tolerated well with no significant adverse events. Clinical and radiological disease appeared to
be suppressed following the treatments and support the expansion of mesenchymal stem cell transplantation into clinical trials
as a potential novel therapy for patients with aggressive MS.
Zhi-cheng Xiao, PhD. He received a Doctor of Natural Science Degree from Swiss Federal Institute of Technology, Zurich. He is current Professor in Monash University. He is the CEO & CFO of iRiccorgPharm, a premier Bio-Tech company. He has published more than 100 papers in reputed journals and serving as editorial board members of more than 10 journals.